Miami Cancer Institute

Summary

Miami Cancer Institute is a medical facility located in Miami, Florida. This center is recognized for care of Cancer, Brain Tumor, Breast Cancer, Lung Cancer, Pancreatic Cancer and other specialties. Miami Cancer Institute is involved with conducting 200 clinical trials across 322 conditions. There are 29 research doctors associated with this hospital, such as Rupesh R Kotecha, MD, Doured Daghistani, Guenther Koehne, MD, PhD, and Michael Chuong, MD.

Top PIs

Clinical Trials running at Miami Cancer Institute

Brain Tumor

Breast Cancer

Lung Cancer

Cancer

Skin Cancer

Kidney Cancer

Pancreatic Cancer

Bladder Cancer

Glioblastoma

Breast cancer

Radiation Therapy vs Observation

for Meningioma

This trial studies if radiation therapy helps prevent the return of grade II meningioma after surgery. Radiation therapy uses powerful x-rays to destroy any leftover cancer cells. The goal is to see if this improves patient outcomes compared to just monitoring them. Radiation therapy has shown success in stabilizing tumor growth and reducing recurrence risk.

Recruiting

2 awards

Phase 3

12 criteria

Radiation Therapy

for Brain Metastasis

This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. FSRS delivers a high dose of radiation to the tumor over 3 treatments. SRS is a type of external radiation therapy that uses special equipment to position the patient and precisely give a single large dose of radiation to a tumor. FSRS may be more effective compared to SRS in treating patients with cancer that has spread to the brain.

Recruiting

2 awards

Phase 3

12 criteria

Electric Field Therapy + Bevacizumab

for Meningioma

The purpose of this research study is to determine the effects bevacizumab (the study drug) combined with Optune (the study device) tumor treatment field therapy has on meningiomas. Bevacizumab is considered investigational because the US Food and Drug Administration (FDA) has not approved its use for the treatment of meningiomas. The study drug is a medication that blocks the growth of new blood vessels. It is thought that the study drug may interfere with the growth of new blood vessels and therefore might stop tumor growth, and possibly shrink the tumor by keeping it from receiving nutrients and oxygen supplied by the blood vessels. Optune is also considered investigational because the US FDA has not approved its use for the treatment of meningiomas. Optune is a device that the patient will wear and use for at least 18 hours of each day. It delivers alternating electrical current to the patient's brain tumor and by doing so interrupts a process called mitosis. Mitosis needs to occur in order for cell division to occur and allows tumors to grow. By slowing this process, we hypothesize that meningioma growth may also be slowed.

Recruiting

1 award

Phase 2

12 criteria